Hyperfine announces Q3 earnings per share of 14 cents, unchanged from last year.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 13 2025
0mins
Should l Buy HYPR?
Q3 Revenue Performance: Hyperfine, Inc. reported Q3 revenue of $3.4 million, a slight decrease from $3.6 million in the same period last year.
Growth Catalysts: The company highlighted the launch of its next generation Swoop(R) system and Optive AITM software, along with its entry into the neurology office market, as key growth drivers.
Positive Feedback: Initial feedback from the first 100 days post-launch of the Swoop(R) system indicates strong potential for broad adoption across various care sites.
Future Outlook: CEO Maria Sainz expressed confidence that these developments will diversify and accelerate growth, ultimately enhancing financial performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HYPR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HYPR
Wall Street analysts forecast HYPR stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.150
Low
2.00
Averages
2.00
High
2.00
Current: 1.150
Low
2.00
Averages
2.00
High
2.00
About HYPR
Hyperfine, Inc. is a health technology company. The Company is engaged in providing patient care globally through artificial intelligence (AI)-powered portable ultra-low-field (ULF) magnetic resonance (MR) brain imaging. Its Swoop Portable MR Imaging System (Swoop system) produces images at a lower magnetic field strength than conventional magnetic resonance imaging (MRI) scanners. Its Swoop system is designed to transform brain MR for the patient, the clinician and the provider, enabling a highly differentiated experience for patients, timely imaging for clinicians, and favorable economics for hospital administrators. The Swoop system is a portable ULF MRI device for producing images that display the internal structures of the head where full diagnostic examination is not clinically practical. The Swoop system is FDA-cleared for brain imaging of patients of all ages. The Swoop system is commercially available in a select number of international markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Hyperfine Secures $40M Loan for Swoop System Expansion
- Funding Support: Hyperfine has secured a $40 million loan from Horizon Technology, with an initial $15 million available at closing and up to $25 million for future commercial initiatives, significantly enhancing the market competitiveness of its Swoop system.
- Technological Innovation: The Swoop system, which has received FDA clearance, offers AI-powered point-of-care brain imaging in various settings such as ICUs, emergency departments, and smaller community hospitals, thereby improving accessibility to medical services.
- Market Outlook: Horizon's Chief Investment Officer Paul Seitz noted that Hyperfine's technology platform expands access to brain imaging in environments where conventional MRI is not feasible, showcasing strong clinical and economic evidence that indicates a broad commercial opportunity.
- Global Expansion Plans: Hyperfine CEO Maria Sainz stated that this financing will accelerate the commercial expansion of the Swoop system across hospitals and clinics, aiming to provide high clinical and economic value MRI services for acute and chronic brain conditions.
See More
Horizon Grants $40 Million Loan Facility to Hyperfine, with $15 Million Disbursed at Closing
Loan Facility Announcement: Hyperfine Inc. has secured a $40 million loan facility to support its operations and growth.
Funding Details: The loan is backed by a $15 million funding commitment that was finalized at closing.
See More
Hyperfine (HYPR) Q4 2025 Earnings Call Transcript
See More
Hyperfine Inc Reports Strong Q4 Earnings with Significant Growth
- Significant Revenue Growth: Hyperfine Inc reported Q4 2025 revenue of $5.3 million, a 128% increase from the previous year, demonstrating strong performance in the next-generation Swoop scanner market and indicating potential for future sales growth.
- Gross Margin Expansion: The company achieved a gross margin of 50.9% in Q4, representing a 1,530 basis point increase year-over-year, highlighting successful cost control and pricing strategies that enhance its competitive position in the market.
- Reduced Cash Burn: Net cash burn for Q4 2025 was $5.7 million, down 30% year-over-year, reflecting improved financial discipline and operational efficiency, which is likely to boost investor confidence.
- Optimistic 2026 Outlook: Hyperfine anticipates 2026 revenue between $20 million and $22 million, representing a 55% growth at the midpoint, with gross margin guidance set at 50% to 55%, indicating a positive outlook on future market opportunities.
See More
Hyperfine, Inc. Reports Strong Q4 2025 Earnings and Growth Outlook
- Significant Revenue Growth: Hyperfine reported Q4 2025 revenue of $5.3 million, a 128% increase year-over-year, demonstrating strong market performance with the next-generation Swoop system and solidifying its leadership in portable MRI technology.
- Gross Margin Improvement: The company achieved a gross margin of 50.9% in Q4, representing a 1,530 basis point increase from Q4 2024, indicating substantial progress in cost control and operational efficiency, which will enhance future profitability.
- Geographic Expansion Opportunities: The approval of the Swoop system in India opens new market expansion opportunities, with management emphasizing operational milestones in innovation, clinical, and economic evidence generation throughout 2025, laying a foundation for future growth.
- Optimistic 2026 Outlook: Hyperfine expects revenue for 2026 to range between $20 million and $22 million, reflecting a midpoint year-over-year growth of 55%, while gross margins are projected to remain between 50% and 55%, showcasing the company's confidence in future market demand.
See More
Hyperfine Q4 Earnings Beat Expectations with Significant Revenue Growth
- Earnings Highlights: Hyperfine's Q4 GAAP EPS of -$0.06 beats expectations by $0.02, indicating an improvement in profitability despite still being in the red.
- Revenue Surge: Q4 revenue reached $5.29M, a 128.0% year-over-year increase, although it slightly missed expectations by $0.01M, reflecting strong market demand and business expansion capabilities.
- Future Projections: Management anticipates full-year 2026 revenue to be approximately $20 to $22 million, representing a 55% growth at the midpoint compared to 2025, showcasing confidence in future growth.
- Cash Flow Management: Expected cash burn for 2026 is projected to be around $26 to $28 million, indicating a 10% decline at the midpoint compared to 2025, demonstrating efforts in cost control and resource optimization.
See More
Hyperfine Secures $40M Loan for Swoop System Expansion
- Funding Support: Hyperfine has secured a $40 million loan from Horizon Technology, with an initial $15 million available at closing and up to $25 million for future commercial initiatives, significantly enhancing the market competitiveness of its Swoop system.
- Technological Innovation: The Swoop system, which has received FDA clearance, offers AI-powered point-of-care brain imaging in various settings such as ICUs, emergency departments, and smaller community hospitals, thereby improving accessibility to medical services.
- Market Outlook: Horizon's Chief Investment Officer Paul Seitz noted that Hyperfine's technology platform expands access to brain imaging in environments where conventional MRI is not feasible, showcasing strong clinical and economic evidence that indicates a broad commercial opportunity.
- Global Expansion Plans: Hyperfine CEO Maria Sainz stated that this financing will accelerate the commercial expansion of the Swoop system across hospitals and clinics, aiming to provide high clinical and economic value MRI services for acute and chronic brain conditions.
See More
Horizon Grants $40 Million Loan Facility to Hyperfine, with $15 Million Disbursed at Closing
Loan Facility Announcement: Hyperfine Inc. has secured a $40 million loan facility to support its operations and growth.
Funding Details: The loan is backed by a $15 million funding commitment that was finalized at closing.
See More
Hyperfine (HYPR) Q4 2025 Earnings Call Transcript
See More
Hyperfine Inc Reports Strong Q4 Earnings with Significant Growth
- Significant Revenue Growth: Hyperfine Inc reported Q4 2025 revenue of $5.3 million, a 128% increase from the previous year, demonstrating strong performance in the next-generation Swoop scanner market and indicating potential for future sales growth.
- Gross Margin Expansion: The company achieved a gross margin of 50.9% in Q4, representing a 1,530 basis point increase year-over-year, highlighting successful cost control and pricing strategies that enhance its competitive position in the market.
- Reduced Cash Burn: Net cash burn for Q4 2025 was $5.7 million, down 30% year-over-year, reflecting improved financial discipline and operational efficiency, which is likely to boost investor confidence.
- Optimistic 2026 Outlook: Hyperfine anticipates 2026 revenue between $20 million and $22 million, representing a 55% growth at the midpoint, with gross margin guidance set at 50% to 55%, indicating a positive outlook on future market opportunities.
See More
Hyperfine, Inc. Reports Strong Q4 2025 Earnings and Growth Outlook
- Significant Revenue Growth: Hyperfine reported Q4 2025 revenue of $5.3 million, a 128% increase year-over-year, demonstrating strong market performance with the next-generation Swoop system and solidifying its leadership in portable MRI technology.
- Gross Margin Improvement: The company achieved a gross margin of 50.9% in Q4, representing a 1,530 basis point increase from Q4 2024, indicating substantial progress in cost control and operational efficiency, which will enhance future profitability.
- Geographic Expansion Opportunities: The approval of the Swoop system in India opens new market expansion opportunities, with management emphasizing operational milestones in innovation, clinical, and economic evidence generation throughout 2025, laying a foundation for future growth.
- Optimistic 2026 Outlook: Hyperfine expects revenue for 2026 to range between $20 million and $22 million, reflecting a midpoint year-over-year growth of 55%, while gross margins are projected to remain between 50% and 55%, showcasing the company's confidence in future market demand.
See More
Hyperfine Q4 Earnings Beat Expectations with Significant Revenue Growth
- Earnings Highlights: Hyperfine's Q4 GAAP EPS of -$0.06 beats expectations by $0.02, indicating an improvement in profitability despite still being in the red.
- Revenue Surge: Q4 revenue reached $5.29M, a 128.0% year-over-year increase, although it slightly missed expectations by $0.01M, reflecting strong market demand and business expansion capabilities.
- Future Projections: Management anticipates full-year 2026 revenue to be approximately $20 to $22 million, representing a 55% growth at the midpoint compared to 2025, showcasing confidence in future growth.
- Cash Flow Management: Expected cash burn for 2026 is projected to be around $26 to $28 million, indicating a 10% decline at the midpoint compared to 2025, demonstrating efforts in cost control and resource optimization.
See More
